¹**TITLE**

²ENDOTHELIAL CELL-DERIVED EXTRACELLULAR VESICLES ELICIT ³NEUTROPHIL DEPLOYMENT FROM THE SPLEEN FOLLOWING ACUTE ⁴MYOCARDIAL INFARCTION

5

⁶**One Sentence Summary**

⁷Extracellular vesicles mediate neutrophil mobilisation from the spleen following acute ⁸myocardial infarction.

9

¹⁰**Authors**

11 Naveed Akbar¹, Adam T. Braithwaite¹, Emma M. Corr², Graeme J. Koelwyn², Coen 12 van Solingen², Clément Cochain³, Antoine-Emmanuel Saliba⁴, Alastair Corbin⁵, 13 Daniela Pezzolla¹, Laurienne Edgar¹, Mala Gunadasa-Rohling⁶, Abhirup Banerjee¹, 14 Daan Paget¹, Charlotte Lee¹, Eleanor Hogg¹, Adam Costin⁷, Raman Dhaliwal⁷, Errin 15 Johnson⁷, Thomas Krausgruber 8 , Joey Riepsaame⁷, Genevieve E. Melling 9 , 16 Mayooran Shanmuganathan^{1, 10, 11}, Oxford Acute Myocardial Infarction Study 17 (OxAMI)^{1, 10, 11}, Christoph Bock^{8,12}, David R. F Carter⁹, Keith M. Channon^{1, 10, 11}, Paul 18 R. Riley⁶, Irina A. Udalova⁵, Kathryn J. Moore², Daniel Anthony¹³, Robin P. 19 $Choudhurv^{1, 10, 11}$ </sup>

20

²¹**Affiliations**

 122 $^{-1}$ Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of 23 Oxford.

24 ²NYU Cardiovascular Research Center, Department of Medicine, Division of

25 Cardiology, School of Medicine, New York University School of Medicine

- ³ Comprehensive Heart Failure Center, University Hospital Wurzburg, Germany
- ⁴Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz-Center for
- 28 **Infection Research (HZI)**
- ⁵ Kennedy Institute of Rheumatology, University of Oxford.
- ⁶ Department of Physiology, Anatomy and Genetics, University of Oxford.
- ⁷ Sir William Dunn School of Pathology, University of Oxford.
- ⁸CeMM Research Center for Molecular Medicine of the Austrian Academy of
- 33 Sciences, Vienna, Austria.
- ⁹ Department of Biological and Medical Sciences, Oxford Brookes University.
- ¹⁰ The OxAMI Study is detailed in the Supplemental Acknowledgments.
- ¹¹ Acute Vascular Imaging Centre, Radcliffe Department of Medicine, University of
- 37 Oxford.
- ¹² Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
- ¹³ Department of Pharmacology, University of Oxford.
- 40

⁴¹**Corresponding Author**

- 42 Professor Robin Choudhury
- ⁴³Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of
- 44 Oxford.
- 45 robin.choudhury@cardiov.ox.ac.uk

⁴⁶**Abstract**

Acute myocardial infarction rapidly increases blood neutrophils (<2 hours). Release of neutrophils from bone marrow, in response to chemokine elevation, has been 49 considered their source, but chemokine levels peak up to 24 hours after injury, and *after* neutrophil elevation. This suggests that additional non chemokine-dependent 51 processes may be involved. Endothelial cell (EC) activation promotes the rapid $\left($ < 30 minutes) release of extracellular vesicles (EVs), which are enriched in vascular cell 53 adhesion molecule-1 (VCAM-1) and miRNA-126, and are thus a potential mechanism for communicating with remote tissues.

⁵⁵Here, we show that injury to the myocardium rapidly mobilises neutrophils from the 56 spleen to peripheral blood and induces their transcriptional activation prior to their 57 arrival at injured tissue. Ischemic myocardium leads to the generation and release of ⁵⁸EC-derived-EVs bearing VCAM-1. EC-EV delivery to the spleen alters inflammatory ⁵⁹gene and chemokine protein expression, and mobilises neutrophils to peripheral ⁶⁰blood. Using CRISPR/Cas9 genome editing we generated VCAM-1-deficient EV and 61 showed that its deletion removed the ability of EC-EV to provoke the mobilisation of ⁶²neutrophils. Furthermore, inhibition of miRNA-126 *in vivo* reduced myocardial 63 infarction size in a mouse model. Our findings show a novel mechanism for the rapid ⁶⁴mobilisation of neutrophils to peripheral blood from a splenic reserve, independent of 65 classical chemokine signalling, and establish a proof of concept for functional ⁶⁶manipulation of EV-communications through genetic alteration of parent cells.

Introduction

Acute myocardial infarction (AMI) is a substantial sterile injury that leads to a rapid increase in peripheral blood neutrophils (*1-5*). Elevated peripheral blood neutrophil 71 number post-AMI correlates with the extent of myocardial injury, degree of cardiac dysfunction, and mortality (*1-3*). Defective neutrophil removal enhances susceptibility 73 to cardiac rupture (6) and inhibition of neutrophil recruitment in AMI reduces infarct size (*1*), but antibody depletion of neutrophils prior to AMI increases infarct size, 75 enhances fibrosis and lowers the number of M2 macrophages in the healing myocardium (*1, 7*). These findings suggest a complex role for neutrophils in the 77 contexts of myocardial ischaemic injury and repair.

The bone marrow is the primary site for granulopoiesis (*8, 9*) and has been regarded as the principal source of neutrophils that are mobilised to peripheral blood after injury (*4, 10*). Mature neutrophils are held in large numbers in the haemopoietic cords, separated from the blood by the sinusoidal endothelium (*11*). In the current 82 paradigm, these cells are retained in the marrow by the interaction of CXCR4 and CXCL12 (stromal cell derived factor (SDF-1α)) (*12*) and mobilised in response to 84 soluble factors. Intravascular injection of a range of chemotactic factors, including leukotriene B4, C5a, interleukin-8 (IL-8) (*13*), CXCL chemokines (*12, 14*) and granulocyte-colony stimulating factor (G-CSF) (*15, 16*) can drive the rapid mobilisation of neutrophils across the sinusoidal endothelium. However, numerous 88 strands of evidence question whether chemokines derived from injured tissues are responsible for very early neutrophil mobilisation *in vivo*. Intra-cardiac mRNA levels for cytokines peak 12 hours after injury (*17*) and pro-inflammatory proteins are very modestly elevated in coronary sinus following reperfusion therapy in AMI (*18, 19*). Furthermore, *in vivo* blood chemokine profiles peak 24 hours post-AMI and do not

93 precede the rise in blood neutrophil counts in humans or mice, which occurs within 2 ⁹⁴hours in mice following injury (*1, 20*). Moreover, a putative source of chemokine ⁹⁵generation in the acutely ischemic myocardium prior to neutrophil infiltration has not 96 been identified.

⁹⁷These observations suggest that neutrophils may be mobilised from alternative 98 reserves following injury and by mechanisms that are not dependent on chemokines. ⁹⁹One possible source is extramedullary haematopoiesis in the spleen (*21*) from where ¹⁰⁰neutrophils are mobilised to peripheral blood following bacterial infection (*22*). By 101 analogy, it is known that monocytes are deployed from a splenic reserve and not 102 from the bone marrow following sterile injury in mice (23), and that this can be driven ¹⁰³by extracellular vesicles (EVs) that are derived from the vascular endothelium (*24*).

¹⁰⁴EVs are membrane-enclosed envelopes (*25*) that are actively secreted by many cell ¹⁰⁵types (*26-28*). These vesicles bear bioactive cargo that includes proteins and 106 microRNAs (miRNAs), which are derived from the parent cell. EV can alter the ¹⁰⁷biological function and cellular status of cells locally (*29*) and remotely following ¹⁰⁸liberation into the blood (*30*). Endothelial cell (EC) derived-EVs bearing vascular cell 109 adhesion molecule-1 (VCAM-1) are elevated in the blood following AMI (24, 29) and 110 have a role in the mobilisation and transcriptional programming of splenic monocytes 111 in AMI (24).

112 Here, we sought to establish whether EC-EVs contribute to the mobilisation and 113 programming of neutrophils and, if so, through which of their component parts. We 114 hypothesised that EC-EVs released during ischaemia would localise to neutrophils in 115 remote reserves in a process mediated by VCAM-1, which has been shown to bind 116 to neutrophils via surface integrins (31). Furthermore, we reasoned that once 117 localised to neutrophils in reserve pools, EC-EV miRNA cargo could induce 118 functionally relevant transcriptional programmes in those target tissues and cells 119 prior to recruitment to the injured myocardium. An understanding of these 120 mechanisms would immediately suggest possibilities for cell-selective immuno-¹²¹modulatory interventions that are relevant in AMI and, potentially, other pathologies 122 with an inflammatory component.

123 Accordingly, we investigated changes in the number and composition of EC-EVs in ¹²⁴mice and humans in the context of AMI, examined their tissue distribution and effects 125 on cell mobilisation and programming *in vitro* and *in vivo*. We used bioinformatics 126 techniques to identify plausible bioactive candidates and evaluated their functional 127 significance experimentally *in vivo* using antagomir and gene editing approaches.

¹²⁸**Results**

¹²⁹**Plasma neutrophil number correlates with the extent of AMI**

130 During acute ST-segment-elevation AMI (STEMI) in human patients (median time 131 from onset of symptoms 3 hours) peripheral blood neutrophil number at the time of 132 presentation correlated with the extent of ischaemic injury, as determined by oedema ¹³³estimation on T2-weighted magnetic resonance imaging (MRI) images obtained 134 within 48 hours of AMI (R^2 =0.365, P=0.017) (**Figure 1A**) and with final infarct size, 135 determined by late gadolinium enhancement (LGE) MRI 6 months post-AMI (R^2 ¹³⁶=0.507, P=0.003) (**Figure 1B**).

137

¹³⁸**AMI mobilises neutrophils from the spleen**

This rapid increase in peripheral blood neutrophils would be consistent with mobilisation from an existing reserve. To determine the source of neutrophil mobilisation in the immediate hours post-AMI we performed left anterior descending (LAD) artery ligation in a mouse model of AMI and analysed cell populations from multiple tissue sources, 2 hours after AMI, by flow cytometry (**Figure 1C**). AMI 144 induced a 6.3 -fold (P<0.01) increase in peripheral blood neutrophils (Live, CD45⁺, 145 CD11b⁺, Ly6G⁺) and simultaneously lowered splenic-neutrophil number by 0.7-fold (P<0.001) (**Figure 1D**). As described previously, to obtain an indication of the mobilisation between reserves, we calculated a neutrophil mobilisation ratio (*24*) (peripheral blood neutrophils/ splenic [or bone marrow] neutrophils) and found an 149 increase in splenic neutrophil-mobilisation (8.5-fold) (P<0.01), but no alteration in 150 bone marrow neutrophil number relative to control animals. There was no alteration 151 in CD62L/L-selectin (which is shed during neutrophil activation) in mobilised

peripheral blood neutrophils (**Figure 1E)**. At this very early time point (2 hours post-153 AMI), we found no differences in LvC6^{high} monocyte number in the peripheral blood or spleen, indicating that neutrophils mobilise from the spleen prior to splenic-monocyte mobilisation (*23*) **(Figure 1F)**.

156

¹⁵⁷**Plasma EVs correlate with the extent of injury and neutrophil count in AMI**

158 Following AMI EC-EVs are significantly augmented in peripheral blood, with plasma-¹⁵⁹EVs showing enrichment for miRNA-126 and the integrin VCAM-1 (*24, 29*). In 160 agreement with our previous findings, patients with AMI had significantly more 161 plasma EVs at time of presentation (24.3 x 10 8 ± 25.7 EV / mL) versus a 6 month 162 follow-up measurement (11.0 x 10 8 \pm 12.5 EV / mL, P<0.01) but they exhibited a 163 similar EV size distribution profile, with a significant elevation in EVs in the size ¹⁶⁴range 100-200 nm diameter (**Figure 2A/B**). Plasma EV number at presentation was 165 significantly correlated with the extent of ischaemic injury as determined by T2-166 weighted MRI $(R^2=0.459, P=0.006)$ (**Figure 2C**) and with the extent of myocardial scarring as determined by LGE at 6 months post-AMI (R²=0.423, P=0.009) (**Figure** ¹⁶⁸**2D**). We also found a highly significant relationship between plasma-EV number and 169 peripheral blood neutrophil number $(R^2=0.753, P<0.001)$ at time of presentation ¹⁷⁰(**Figure 2E**), consistent with a possible role for plasma-EVs in neutrophil mobilisation 171 post-AMI.

172

¹⁷³**EC-EVs are enriched for miRNA-126**

¹⁷⁴In AMI, the total EV pool is enriched for EVs bearing VCAM-1 (*24*). Endothelial cells ¹⁷⁵are activated in AMI (*32*) and express VCAM-1 in response to ischaemia *in vivo* (*33*)

and to pro-inflammatory cytokines such as tumour necrosis factor-α (TNF-α) *in vitro* (*34*). In order to probe the function of EVs-derived exclusively from activated endothelial cells we studied primary human umbilical cord vein endothelial cells *in vitro*. Compared with basal conditions, treatment of endothelial cells with pro-180 inflammatory TNF-α activated endothelial cells as evidenced by enhanced VCAM-1 181 protein expression (P<0.001) (Figure 3 A) and increased EV production (P<0.001) (**Figure 3B/C)**, with a significant increase in small EVs, of similar size range (100- 200 nm) to those found to increase in patients with AMI. EC-EVs displayed typical EV morphology (**Figure 3D/E)**, the EV-protein marker CD9 **(Figure 3F)** and were 185 positive for endothelial nitric oxide synthase (eNOS). EV-depleted cell culture 186 supernatants and cell culture media that had not been exposed to cells were negative for CD9 and eNOS, confirming robust EC-EV generation and isolation. EC-EV preparations were negative for histone and mitochondrial markers of cellular 189 contamination, which were readily detected in endothelial cell pellets but not in isolated EC-EVs or in EV-depleted cell culture supernatants (**Figure 3F)**.

EC-EVs derived from pro-inflammatory stimulations show significant enrichment for miRNA-126-3p (P<0.01) (**Figure 3G)** and miRNA-126-5p (P<0.01) (**Figure 3H)**, 193 consistent with previous observations of changes in miRNA, measured in the unselected EV pool, following AMI (*24*).

miRNA-126-mRNA targets cluster selectively in neutrophil motility pathways

To explore the potential role of EC-EV-miRNA-126 we employed *in silico* bioinformatics techniques. We curated miRNA-126 putative mRNA target genes from 3 different miRNA-mRNA target prediction databases for human and the mouse. Our

²⁰⁰curated lists comprised targets from TargetScanHuman, TargetScanMouse (*35*), ²⁰¹miRWalk (*36*) and miRDB (*37*).

²⁰²We determined whether the mRNAs putatively regulated by miRNA-126 for the 203 human, mouse or the overlap gene set (targeted in both the human and mouse) ²⁰⁴(**Figure 3I/3J and Supplementary Table 1/2**) were present in Gene Ontology (GO) 205 terms for neutrophil function. miRNA-126-putative-mRNA targets were significantly 206 overrepresented when compared by Fisher's exact test to neutrophil pathway GO 207 terms for neutrophil migration (GO: GO1990266) in the human (P <0.001), the ²⁰⁸mouse (P<0.001) and the overlap gene set (P<0.001) (**Supplementary Table 3**). ²⁰⁹Similarly, miRNA-126-putative-mRNA targets were significantly overrepresented 210 when compared to the neutrophil pathway GO term for neutrophil chemotaxis (GO: 211 GO0030593) in the human (P <0.001), the mouse (P < 0.001) and the overlap gene 212 set (P<0.001) (**Supplementary Table 3**). Whereas, other neutrophil GO terms such 213 as neutrophil mediated killing of a fungus (GO: GO0070947), neutrophil clearance ²¹⁴(GO: GO0097350) and regulation of neutrophil mediated cytotoxicity (GO: 0070948) 215 were not enriched (**Supplementary Table 3**), suggesting a possible role for EC-EV-²¹⁶miRNA-126 in orchestrating processes related to neutrophil mobilisation post-AMI.

²¹⁸**AMI alters neutrophil transcriptomes**

²¹⁹To determine whether neutrophil transcriptomes are altered post-AMI we obtained 220 peripheral blood neutrophils from newly recruited patients presenting with STEMI (N $221 = 3$) and non-STEMI (NSTEMI) control patients (N = 3) at time of presentation and ²²²matched-control samples one month later. STEMI patients had a greater number of 223 differentially expressed genes at time of presentation vs NSTEMI control patients ²²⁴(STEMI 933 genes vs NSTEMI 8 genes) (**Figure 4A-C**). Differentially expressed 225 neutrophil transcriptomes in STEMI patients were determined by Gene Set ²²⁶Enrichment Analysis (GSEA) to be positively enriched at time of presentation for ²²⁷inflammatory pathways, including TNF-α signalling via NF-κB (P<0.001), 228 inflammatory response ($P<0.001$) and interleukin-6 (IL-6) signalling via JAK-STAT3 ²²⁹(P<0.001) (**Figure 4D**).

230 To further understand the potential target pathways for the differentially enriched 231 genes in blood neutrophils following AMI we used GO term enrichment analysis and 232 ranked by false discovery rate (FDR)-adjusted p-values. GO analysis showed that 233 differentially expressed neutrophil genes at the time of presentation favoured 234 pathways for signal recognition particle (SRP)-dependent co-translational protein 235 targeting to membrane (GO:0006614) (P<0.001) and co-translational protein ²³⁶targeting to membrane (GO:0006613) (P<0.001) (**Supplementary Table 4**). ²³⁷Similarly, we used Reactome pathway analysis (*38*) to further explore target 238 pathways for the differentially enrichment genes at the time of presentation and 239 found SRP-dependent co-translational protein targeting to membrane (R-HSA-²⁴⁰1799339) (P<0.001) and neutrophil degranulation (R-HSA-6798695) (P<0.001) to be 241 significantly enriched (**Supplementary Table 4**).

242 Next, we used single cell (sc)-RNA-sequencing data to determine whether neutrophil 243 populations in the peripheral blood of mice subjected to AMI exhibited similar 244 transcriptomic alterations prior to recruitment to the heart. We found differential 245 enrichment in neutrophil populations in the blood following AMI (39), which favoured ²⁴⁶GO terms for neutrophil aggregation (GO:0070488) (**Supplementary Table 5 and 6**) ²⁴⁷(P<0.05), platelet activation (GO:0030168) (P<0.001) (**Supplementary Table 7**) and 248 Reactome pathways for SRP-dependent co-translational protein targeting to ²⁴⁹membrane (R-HSA-1799339) (P<0.001) (**Supplementary Table 5 and 6)** (P<0.001) ²⁵⁰and platelet activation, signalling and aggregation (R-HSA-76002) (P<0.001) ²⁵¹(**Supplementary Table 7**).

These analyses show that in both human and mouse neutrophils transcription is 253 differentially regulated in AMI. We further explored commonality between the human and the mouse transcriptome response following AMI using GO terms (biological 255 process, molecular function and cellular component) and Reactome pathways 256 analysis. There were significant overlaps between the genes that are differentially expressed following AMI in the blood of the human and the mouse (P<0.001) (**Supplementary Table 8**) and significant similarity in target pathways between the 259 human and mouse (**Supplementary Table 9**), demonstrating that patterns of gene expression are conserved and occur *prior* to recruitment to the injured heart. We ranked the significant comparisons by size of their intersect and found that sc-RNA-262 sequencing mouse blood neutrophil populations shared 38% similarity (P<0.001) and 37% similarity (P<0.001), respectively, to target pathways in human neutrophils following AMI (**Supplementary Table 9)**.

²⁶⁶**miRNA-126-mRNA targets are overrepresented in neutrophil transcriptomes**

²⁶⁷**following AMI**

²⁶⁸Human miRNA-126-mRNA targets were significantly overrepresented in human 269 neutrophil transcriptomes at the time of injury (P<0.05) (**Supplementary Table 10**). 270 There was no association between the differentially expressed genes in the mouse 271 blood neutrophil sc-RNA-sequencing populations and miRNA-126-mRNA targets ²⁷²(**Supplementary Table 10**), but neutrophils within the myocardium displayed 273 differential enrichment for miRNA-126-mRNA targets (**Supplementary Table 10**). 274 There was significant enrichment for miRNA-126-mRNA targets from the human, 275 mouse and the overlap lists $(P<0.001)$, consistent with a role for miRNA-126 in 276 regulating neutrophil gene expression following AMI.

277 To test the functional significance of these findings, we treated wild-type mice with 278 an antagomiR for miRNA-126 (n = 5) or a scramble control (n = 7) prior to induction 279 of experimental AMI to assess the role of miRNA-126 on infarct size (**Figure 4E**) and 280 found a 12% reduction in infarct size in animals that received the miRNA-126 281 antagomir versus the scramble control (P<0.01) (**Figure 4F**).

282

²⁸³**EC-EVs localise to the spleen**

284 These accumulating data suggest that EC-EVs, enriched for miRNA-126 and VCAM-285 1 provide an 'ischaemia signal' to neutrophils in the spleen, resulting in mobilisation 286 and transcriptional activation. Accordingly, we tested whether EC-EV localised to the 287 spleen after intravenous injection and whether there were consequent alterations in 288 neutrophil-associated chemokine gene and protein expression. Primary mouse and 289 human endothelial cells release more EVs following inflammatory stimulation (24)

²⁹⁰and hypoxia (*40*). In agreement with these data and our previous observations, 291 mouse sEND.1 endothelial cells produced EV under basal conditions and released 292 significantly more EVs after pro-inflammatory stimulation with TNF-α (P<0.001) ²⁹³(**Figure 5A/B)** (*24*). We confirmed endothelial cell activation by TNF-α by probing for ²⁹⁴VCAM-1 protein and found significantly more protein (P<0.001) (**Figure 3C**). EC-EVs 295 displayed typical EV morphology (**Figure 5D/E)**, EV-protein markers ALIX, TSG101 296 and CD9 (Figure 5F) and were positive for eNOS and VCAM-1. EV-depleted cell 297 culture supernatants and cell culture media that had not been exposed to cells were 298 negative for ALIX, TSG101, CD9, eNOS and VCAM-1, confirming robust EC-EV 299 isolation. EC-EVs derived from pro-inflammatory stimulations showed significant ³⁰⁰enrichment for miRNA-126-3p (P<0.001) (**Figure 5G)** and miRNA-126-5p (P<0.01) ³⁰¹(**Figure 5H)**, indicating similarities in the EC-EV response between human and 302 mouse endothelial cells. We labelled the mouse EC-EV by transfection with non-³⁰³mammalian miRNA-39, which belongs to *C. elegans* and allows quantitative tracing 304 of EVs *in vivo* (**Figure 6A**). This EC-EV labelling approach showed that EC-EVs 305 accumulated rapidly in the spleen and were detectable 2 hours, 6 hours (P<0.001) ³⁰⁶and 24 hours (P<0.001) post-intravenous injection (**Figure 6A)**.

307

³⁰⁸**EC-EVs alter chemokine and protein expression in the spleen**

³⁰⁹Informed by the earlier *in silico* studies suggesting regulation of neutrophil activation 310 and motility by miRNA-126, we hypothesised that EC-EV localisation in the spleen ³¹¹would alter gene expression within spleen tissue, with a focus on CXC chemokine 312 and cytokine activity.

³¹³EC-EVs induced significantly altered mRNA in expression for *Cxcr2, Itag4, Gapdh* ³¹⁴(all, P<0.05), *Il-1*β*, Cxcl1* (both, P<0.01), *Cxcr4 and Il-6* (both, P<0.001) post-EC-EV 315 injection **(Figure 6B).**

³¹⁶We further determined whether delivery of EC-EVs to the spleen altered chemokine 317 protein levels, including for the retention chemokine CXCL12 / SDF-1. In the same ³¹⁸mice we undertook a quantitative protein-detection array for 25 different proteins that ³¹⁹influence neutrophil function, including CXCL12 / SDF-1 , CCL2 (*41*) and CCL3 (*42*), 320 which are known miRNA-126-mRNA targets and CCL27/ CCL28, which are 321 predicted miRNA-126-mRNA targets. There were significant reductions in ³²²6CKine/CCL21 (P<0.01), BLC/CXCL13 (P<0.05), chemerin/retinoic acid receptor ³²³responder protein 2 (RARRES2) (P<0.01), IL-16 (P<0.05), MCP-5/CCL12 (P<0.05) ³²⁴and CXCL12 / SDF-1. (P<0.05) **(Figure 6C)**. These findings are consistent with a 325 role for EC-EV-miRNA-126 in silencing genes involved in cell retention.

326

³²⁷**Endothelial cell derived EVs mobilise neutrophils from the spleen**

Given the effects of the EC-EVs derived from TNF-α activated cells on gene 329 expression and silencing of retention chemokines, we injected EC-EVs, derived from 330 TNF- α activated endothelial cells, intravenously into healthy wild-type mice vs sham 331 injection (Figure 7A). Flow cytometry (Live, CD45⁺, CD11b⁺, Ly6G⁺) showed that EC-EVs significantly increased the number of circulating peripheral blood neutrophils **(Figure 7B),** and simultaneously lowered splenic-neutrophil numbers in the same mice **(Figure 7B),** confirming splenic neutrophil mobilisation induced by EC-EV. Consistent with our observations in AMI we found that EC-EVs mediated greater neutrophil mobilisation from the spleen $(P<0.001)$ than from the bone marrow ³³⁷**(Figure 7C).** As in the context of AMI, there was no alteration in CD62L/L-selectin ³³⁸expression in blood neutrophils **(Figure 7D).**

339

³⁴⁰**EC-EV VCAM-1 mediates neutrophil mobilisation**

³⁴¹Plasma EVs present VCAM-1 on their surface (**Figure 8A**) and the number of ³⁴²VCAM-1 positive EVs increases after AMI (*24*). Similarly, endothelial cells in culture ³⁴³produce EVs enriched for VCAM-1 following pro-inflammatory stimulation (**Figure** ³⁴⁴**5E**). Given its well-established role in mediating interactions between activated 345 vascular endothelium and circulating leukocytes, we hypothesised that VCAM-1 on 346 EC-EVs might perform the converse role by mediating the capture of circulating EC-³⁴⁷EVs by static neutrophils in the spleen. We used CRISPR-Cas9 base editing of 348 endothelial cells to produce VCAM-1 deficient EC-EVs by introducing a stop codon in 349 the VCAM-1 sequence. To confirm CRISPR-Cas9 editing of VCAM-1 from 350 endothelial cells we stimulated wild-type (WT) and VCAM-1 knock-out (KO) cells with 351 TNF-α. WT mouse endothelial cells expressed more VCAM-1 following inflammatory 352 stimulation (P<0.001) (**Figure 8B/C**), whereas VCAM-1 KO cells did not express ³⁵³VCAM-1, confirming successful CRISPR-Cas9 base editing in endothelial cells. ³⁵⁴VCAM-1 KO cells released EC-EV under basal conditions similar to WT cells (**Figure** ³⁵⁵**8D/E)** but VCAM-1 KO endothelial cells did not release more EVs following ³⁵⁶inflammatory stimulation with TNF-α (**Figure 8D/E)**. WT and VCAM-1 KO EC-EV 357 were positive for EV-markers TSG101 and CD9 but only WT inflammatory derived ³⁵⁸EC-EVs were positive for VCAM-1 (**Figure 8F**). EC-EVs derived from either TNF-^α 359 activated WT or TNF- α activated VCAM-1 KO cells were injected into healthy, wild-360 type mice at the same concentration (1 x 10^9 / mL EC-EVs). Using the miRNA-39-3p

361 labelling technique (described above) we found that VCAM-1 deficient EC-EVs and ³⁶²WT EC-EV accumulate in the spleen at similar levels (**Figure 8G**), but VCAM-1 363 deficient EC-EVs did not induce alteration in gene expression that were comparable ³⁶⁴to WT EC-EVs responses in the spleen for *Il-6* (P<0.001), *Il-1*β (P<0.05) and *Cxcl1* ³⁶⁵(P<0.05**)** (**Figure 8H),** suggesting alter signalling**.** Furthermore, deletion of VCAM-1 366 in EC-EVs prevented mobilisation of splenic neutrophils to peripheral blood when 367 compared to wild-type VCAM-1+ EC-EVs (Figure 8I and 8J).

³⁶⁹**Discussion**

³⁷⁰Mobilisation of neutrophils occurs rapidly after AMI in mice and humans (*1, 3, 4*) and 371 their number in peripheral blood correlates with the extent of myocardial injury (1-3). 372 The bone marrow has been regarded as the principal source for neutrophils that are ³⁷³mobilised to peripheral blood after injury, because (i) it is the primary site for 374 granulopoiesis (8-10); (ii) it contains ample reserves of mature cells and; (iii) ³⁷⁵releases neutrophils in response to injection of exogenous chemokines (*12-16*). ³⁷⁶However, the divergent timings of neutrophil mobilisation (rapid) (*1, 20*) and ³⁷⁷chemokine elevation (delayed) *in vivo* (*17, 18, 43*) suggest that additional processes 378 may be involved.

Here, we have identified a previously unknown mechanism by which ischemic injury 380 to the myocardium signals to mobilization of neutrophils from a splenic reserve. We 381 show that: (i) EC-EV generated under conditions of inflammation are enriched for VCAM-1, miRNA-126-3p and miRNA-126-5p; (ii) EC-EVs are delivered to the spleen, where they alter gene and protein expression; and (iii) induce the mobilisation of splenic neutrophils to peripheral blood. Notably, (iv) these EC-EV effects are dependent on VCAM-1. Furthermore, (v) we show that neutrophil 386 transcriptomes are differentially regulated following AMI, prior to entry into the myocardium. (vi) Targets of miRNA-126 are significantly altered in neutrophil 388 transcriptomes post-AMI and (vii) administration of miRNA-126 antagomir significantly reduces infarct size *in vivo*.

³⁹⁰Mature neutrophils are held in large numbers in the haemopoietic cords through 391 interactions with the neutrophil receptors CXCR4 and CXCL12 (11, 44, 45). Loss of ³⁹²CXCL12 induces an increase in peripheral blood neutrophils. Injection of

³⁹³chemotactic factors (*13*), CXCL chemokines (*12, 14*) and G-CSF (*15, 16*) can drive 394 the rapid mobilisation of neutrophils across the sinusoidal endothelium through 395 alterations in CXCR4-CXCL12.

396 Scrutiny of the relative timings of cytokine elevation after ischaemic injury in relation 397 to neutrophil mobilisation does not support their role in this early mobilisation, since ³⁹⁸both the onset and peaks in neutrophil mobilisation occur prior to those for cytokine ³⁹⁹elevation (*17, 18, 43*). IL-8 injection mobilised neutrophils from the bone marrow ⁴⁰⁰(*13*), but after reperfusion in AMI, even in blood from the coronary sinus (undiluted ⁴⁰¹myocardial effluent), the elevation is modest (0.1-fold) (*18, 19*). Furthermore, we 402 calculate that the absolute concentration based on these physiological ⁴⁰³measurements is approximately 2-3 orders of magnitude less than the concentration ⁴⁰⁴used to elicit neutrophil mobilisation in mice (*14*). Finally, neutrophils are the first 405 cells to arrive in the acutely injured tissue. Neutrophil depletion dampens plasma ⁴⁰⁶chemokines levels following AMI (*7*) and in a mouse air pouch model (*46*). It is not 407 clear which other cells in the profoundly ischaemic myocardium could be capable of 408 the rapid synthesis of chemokines, that would be of sufficient magnitude to mediate 409 neutrophil mobilisation from a remote site such as the bone marrow. The 410 sympathetic nervous system is also activated following AMI and mobilises ⁴¹¹hematopoietic stem cells (HSCs) from the bone marrow (*47*). However, HSCs are 412 immature cells unlike terminally differentiated neutrophils and blood numbers of ⁴¹³HSCs do not peak until >6 hours post-AMI, subsequent to the increase in peripheral 414 blood neutrophils.

⁴¹⁵By contrast, numerous studies have shown that hypoxia promotes the rapid (<30 ⁴¹⁶minutes) release of EVs by endothelial cells (*40*). We show that activated endothelial 417 cells in culture liberate large amounts of EV that contain VCAM-1 in their membranes. Using CRISPR/Cas9 genome base editing of cultured endothelial cells, we generatedVCAM-1-deficient EV and showed that while VCAM-1 was not essential for splenic localisation, its absence removed the ability of EV to provoke 421 the rapid mobilisation of neutrophils. Importantly, EVs are taken up rapidly and selectively by the spleen where they become locally concentrated (*24, 48*), unlike 423 chemokines, which have a systemic effect.

424 Following injury to the myocardium there is a marked increase in VCAM-1-bearing-⁴²⁵EVs. VCAM-1 is a glycoprotein, which is expressed on activated endothelium and 426 has a well-established role in the recruitment of circulating leukocytes by binding ⁴²⁷integrins (*31, 49, 50*), including CD49d (*51*) and CD11b/CD18 (*52*). Therefore, our 428 findings suggest an efficient signalling system, in which neutrophils are activated and 429 mobilised by engaging VCAM-1-bearing EVs that are taken up in the spleen, having ⁴³⁰been released remotely from activated endothelium. A subsequent interaction 431 between neutrophils in circulation and static VCAM-1 on activated endothelial cells 432 mediates their recruitment to the original site of injury.

⁴³³The recruitment of neutrophils to the injured myocardium is an essential step in ⁴³⁴tissue response to injury and repair (*1, 7, 20*) and thus modulating the neutrophil 435 response raises possibilities for immuno-modulatory interventions in selected 436 inflammatory pathologies, including AMI. Peripheral blood neutrophils are elevated at 437 time of presentation with AMI in patients and rapidly increase in peripheral blood 438 following AMI in mice. Here, we show that splenic-neutrophils are rapidly mobilised 439 to peripheral blood by EC-EV bearing VCAM-1. These findings complement the 440 current paradigm in which neutrophils are liberated from bone marrow reserves 441 through elevations in blood chemokines. We demonstrate a novel and efficient 442 signalling mechanism between the injured heart microvasculature and the spleen.

⁴⁴³Endothelial cells are ideally placed for the rapid release of EVs to peripheral blood ⁴⁴⁴during ischemia. EV clearance is rapid and predominately to the spleen, which 445 contains neutrophils in the sup-capsular red pulp. Precisely how neutrophils are 446 retained in the spleen is not known, but our findings suggest that local chemokine 447 signalling may be important, as delivery of endothelial cell derived EVs rich in ⁴⁴⁸miRNA-126 downregulates retention chemokines, including the miRNA-126 target ⁴⁴⁹CXCL12, and induces expression of neutrophil mobilisation signals, namely CXCL1. 450 Importantly, we show that these processes are dependent on EV-VCAM-1, an ⁴⁵¹integrin with a well-documented role in immune cell recruitment. Furthermore, we 452 make a new observation that peripheral blood neutrophils are transcriptionally 453 activated prior to recruitment to the injured myocardium, with a bias towards miRNA-454 126-mRNA targets. Our bioinformatics analysis revealed SRP-dependent co-455 translational protein targeting to membrane as the most significantly enriched 456 pathway that was conserved between the human and the mouse blood neutrophils 457 following AMI. SRP is necessary for transferring newly synthesised nascent proteins 458 from the ribosome, which are destined for cellular excretion. SRP monoallelic 459 mutations induce a congenital blood neutropenia, possibly due to an increase in ⁴⁶⁰susceptibility of neutrophils to apoptosis and the unfolded protein response (*53, 54*). 461 A significant enrichment for the universally conserved SRP supports our conclusion 462 that neutrophils are transcriptionally active prior to recruitment to the injured heart. ⁴⁶³Targeting SRP may open novel opportunities to target neutrophil transcriptomes 464 prior to tissue recruitment to modulate their survival, function and phenotype, thereby ⁴⁶⁵protecting injured tissues from pro-inflammatory neutrophil mediated damage.

⁴⁶⁶In conclusion, we demonstrate that the injured myocardium can rapidly mobilise 467 splenic neutrophils through generation and release of EC-EVs that bear VCAM-1.

⁴⁶⁸These findings provide novel insights into how neutrophils are mobilised to 469 peripheral blood following ischaemic injury, without the need for immediate 470 generation and release of chemokines. EVs are decorated in surface proteins and 471 integrins, which allows them to interact with cells and home to specific sites (55, 56). 472 A functionally efficient reciprocity may operate, in which VCAM-1, on endothelial cell-473 derived EVs is required for the mobilisation of splenic neutrophils, complementing 474 the known role of static VCAM-1 in the recruitment of circulating neutrophils to 475 activated endothelium. Neutrophils are the first cells recruited to the ischemic ⁴⁷⁶myocardium and are a major source of chemokines (*7*). Thus, the well-established 477 mobilisation of neutrophils from bone marrow reserves in response to chemokines ⁴⁷⁸(*12-16*) represent a secondary response, which is consistent with the time course of 479 earlier reports and with our observations that there is no rapid bone marrow 480 mobilisation in the early phase.

⁴⁸¹We have shown proof of concept that genetic manipulation can alter EV properties in 482 functionally important ways. Immunomodulation of the neutrophil and monocyte 483 response to AMI using EV vectors may provide therapeutic opportunities in AMI.

⁴⁸⁵**Materials and Methods**

486 Acute myocardial infarction patients

487 All clinical investigations were conducted in accordance with the Declaration of 488 Helsinki. The Oxfordshire Research Ethics Committee (references 08/H0603/41 and ⁴⁸⁹11/SC/0397) approved human clinical cohort protocols. All patients provided 490 informed written consent for inclusion in the study.

491

492 LAD ligation model

⁴⁹³All animal procedures were approved by an ethical review committee at the 494 University of Oxford or NYU Lagone Health. UK experimental interventions were 495 carried out by UK Home Office personal licence holders under the authority of a 496 Home Office project licence.

497

498 Further experimental details are provided in the supplementary methods.

499

500 Data Availability

⁵⁰¹RNA Sequencing data are deposited at Gene Expression Omnibus. *Pending* 502 accession number.

503

504 Statistical analysis

505 All values are group mean \pm standard deviation (s.d.). Paired and unpaired two-tailed 506 student's t test was used to compare 2 groups, a one-way or two-way analysis of 507 variance (ANOVA) or mixed model effects with post-hoc Bonferroni correction was 508 used to compare multiple group (>2) means with one, two or more independent 509 variables. *p* values <0.05 were considered significant. Hierarchical clustering 510 analysis and generation of heatmap plots was performed using the pheatmap R 511 package v1.0.12.

512

513

⁵¹⁵**References**

- 520 2. T. M. Guo, B. Cheng, L. Ke, S. M. Guan, B. L. Qi, W. Z. Li, B. Yang, Prognostic Value of 521 Neutrophil to Lymphocyte Ratio for In-hospital Mortality in Elderly Patients with Acute 522 Myocardial Infarction. *Curr Med Sci* **³⁸**, 354-359 (2018).
- 523 3. T. Kong, T. H. Kim, Y. S. Park, S. P. Chung, H. S. Lee, J. H. Hong, J. W. Lee, 524 J. S. You, I. Park, Usefulness of the delta neutrophil index to predict 30-day 525 mortality in patients with ST segment elevation myocardial infarction. ⁵²⁶*Scientific reports* **⁷**, 15718 (2017).
- ⁵²⁷4. G. Sreejit, A. Abdel-Latif, B. Athmanathan, R. Annabathula, A. Dhyani, S. K. 528 Noothi, G. A. Quaife-Ryan, A. Al-Sharea, G. Pernes, D. Dragoljevic, H. Lal, K. 529 Schroder, B. Y. Hanaoka, C. Raman, M. B. Grant, J. E. Hudson, S. S. Smyth, ⁵³⁰E. R. Porrello, A. J. Murphy, P. R. Nagareddy, Neutrophil-Derived S100A8/A9 ⁵³¹Amplify Granulopoiesis After Myocardial Infarction. *Circulation* **¹⁴¹**, 1080- 532 1094 (2020).
- ⁵³³5. S. Chia, J. T. Nagurney, D. F. Brown, O. C. Raffel, F. Bamberg, F. Senatore, ⁵³⁴F. J. Wackers, I. K. Jang, Association of leukocyte and neutrophil counts with 535 infarct size, left ventricular function and outcomes after percutaneous ⁵³⁶coronary intervention for ST-elevation myocardial infarction. *The American* ⁵³⁷*journal of cardiology* **¹⁰³**, 333-337 (2009).
- ⁵³⁸6. H. Lorchner, J. Poling, P. Gajawada, Y. Hou, V. Polyakova, S. Kostin, J. M. 539 Adrian-Segarra, T. Boettger, A. Wietelmann, H. Warnecke, M. Richter, T.

- 7. M. Horckmans, L. Ring, J. Duchene, D. Santovito, M. J. Schloss, M. Drechsler, C. Weber, O. Soehnlein, S. Steffens, Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. *European Heart Journal* **³⁸**, 187-197 (2016).
- 8. M. Evrard, I. W. H. Kwok, S. Z. Chong, K. W. W. Teng, E. Becht, J. Chen, J. 548 L. Sieow, H. L. Penny, G. C. Ching, S. Devi, J. M. Adrover, J. L. Y. Li, K. H. 549 Liong, L. Tan, Z. Poon, S. Foo, J. W. Chua, I. H. Su, K. Balabanian, F. Bachelerie, S. K. Biswas, A. Larbi, W. Y. K. Hwang, V. Madan, H. P. Koeffler, 551 S. C. Wong, E. W. Newell, A. Hidalgo, F. Ginhoux, L. G. Ng, Developmental 552 Analysis of Bone Marrow Neutrophils Reveals Populations Specialized in Expansion, Trafficking, and Effector Functions. *Immunity* **⁴⁸**, 364-379 e368 (2018).
- 9. Y. P. Zhu, L. Padgett, H. Q. Dinh, P. Marcovecchio, A. Blatchley, R. Wu, E. Ehinger, C. Kim, Z. Mikulski, G. Seumois, A. Madrigal, P. Vijayanand, C. C. Hedrick, Identification of an Early Unipotent Neutrophil Progenitor with Pro-tumoral Activity in Mouse and Human Bone Marrow. *Cell Rep* **²⁴**, 2329-2341 e2328 (2018).
- 10. M. Horckmans, M. Bianchini, D. Santovito, R. T. A. Megens, J. Y. Springael, I. 561 Negri, M. Vacca, M. Di Eusanio, A. Moschetta, C. Weber, J. Duchene, S. 562 Steffens, Pericardial Adipose Tissue Regulates Granulopoiesis, Fibrosis, and Cardiac Function After Myocardial Infarction. *Circulation* **¹³⁷**, 948-960 (2018).

- ⁵⁶⁴11. R. C. Furze, S. M. Rankin, Neutrophil mobilization and clearance in the bone ⁵⁶⁵marrow. *Immunology* **¹²⁵**, 281-288 (2008).
- ⁵⁶⁶12. C. Martin, P. C. E. Burdon, G. Bridger, J. C. Gutierrez-Ramos, T. J. Williams,
- 567 S. M. Rankin, Chemokines acting via CXCR2 and CXCR4 control the release 568 of neutrophils from the bone marrow and their return following senescence. ⁵⁶⁹*Immunity* **¹⁹**, 583-593 (2003).
- 570 13. T. Terashima, D. English, J. C. Hogg, S. F. van Eeden, Release of 571 polymorphonuclear leukocytes from the bone marrow by interleukin-8. *Blood*
- ⁵⁷²**92**, 1062-1069 (1998).
- ⁵⁷³14. M. A. Jagels, T. E. Hugli, Neutrophil chemotactic factors promote 574 **Example 1 Figure 1 Figure 13** Figure 1574 **III Figure 13 Figure 150 Figure** ⁵⁷⁵marrow. *Journal of immunology* **148**, 1119-1128 (1992).
- ⁵⁷⁶15. C. L. Semerad, F. L. Liu, A. D. Gregory, K. Stumpf, D. C. Link, G-CSF is an 577 essential regulator of neutrophil trafficking from the bone marrow to the blood. ⁵⁷⁸*Immunity* **¹⁷**, 413-423 (2002).
- ⁵⁷⁹16. A. Köhler, K. De Filippo, M. Hasenberg, C. van den Brandt, E. Nye, M. P. ⁵⁸⁰Hosking, T. E. Lane, L. Männ, R. M. Ransohoff, A. E. Hauser, O. Winter, B. 581 Schraven, H. Geiger, N. Hogg, M. Gunzer, G-CSF-mediated thrombopoietin 582 **release triggers neutrophil motility and mobilization from bone marrow via** ⁵⁸³induction of Cxcr2 ligands. *Blood* **¹¹⁷**, 4349-4357 (2011).
- 584 17. A. Deten, H. C. Volz, W. Briest, H. G. Zimmer, Cardiac cytokine expression is 585 upregulated in the acute phase after myocardial infarction. Experimental ⁵⁸⁶studies in rats. *Cardiovascular research* **⁵⁵**, 329-340 (2002).

- 18. F. J. Neumann, I. Ott, M. Gawaz, G. Richardt, H. Holzapfel, M. Jochum, A. 588 Schomig, Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. *Circulation* **⁹²**, 748-755 (1995).
- 19. N. Marx, F.-J. Neumann, I. Ott, M. Gawaz, W. Koch, T. Pinkau, A. Schömig, **Induction of Cytokine Expression in Leukocytes in Acute Myocardial** Infarction. *Journal of the american college of cardiology* **³⁰**, 165-170 (1997).
- 20. M. Horckmans, L. Ring, J. Duchene, D. Santovito, M. J. Schloss, M. Drechsler, C. Weber, O. Soehnlein, S. Steffens, Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. *Eur Heart J* **³⁸**, 187-197 (2017).
- 21. I. Puga, M. Cols, C. M. Barra, B. He, L. Cassis, M. Gentile, L. Comerma, A. 598 Chorny, M. Shan, W. Xu, G. Magri, D. M. Knowles, W. Tam, A. Chiu, J. B. Bussel, S. Serrano, J. A. Lorente, B. Bellosillo, J. Lloreta, N. Juanpere, F. Alameda, T. Baro, C. D. de Heredia, N. Toran, A. Catala, M. Torrebadell, C. 601 Fortuny, V. Cusi, C. Carreras, G. A. Diaz, J. M. Blander, C. M. Farber, G. Silvestri, C. Cunningham-Rundles, M. Calvillo, C. Dufour, L. D. Notarangelo, V. Lougaris, A. Plebani, J. L. Casanova, S. C. Ganal, A. Diefenbach, J. I. Arostegui, M. Juan, J. Yague, N. Mahlaoui, J. Donadieu, K. Chen, A. Cerutti, B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. *Nat Immunol* **¹³**, 170-180 (2011).
- 22. J. F. Deniset, B. G. Surewaard, W. Y. Lee, P. Kubes, Splenic Ly6G(high) mature and Ly6G(int) immature neutrophils contribute to eradication of S. pneumoniae. *J Exp Med* **²¹⁴**, 1333-1350 (2017).

⁶¹¹23. F. K. Swirski, M. Nahrendorf, M. Etzrodt, M. Wildgruber, V. Cortez-Retamozo, ⁶¹²P. Panizzi, J. L. Figueiredo, R. H. Kohler, A. Chudnovskiy, P. Waterman, E. 613 Aikawa, T. R. Mempel, P. Libby, R. Weissleder, M. J. Pittet, Identification of 614 splenic reservoir monocytes and their deployment to inflammatory sites. ⁶¹⁵*Science* **³²⁵**, 612-616 (2009).

- ⁶¹⁶24. N. Akbar, J. E. Digby, T. J. Cahill, A. N. Tavare, A. L. Corbin, S. Saluja, S. 617 **Dawkins, L. Edgar, N. Rawlings, K. Ziberna, E. McNeill, S. Oxford Acute** ⁶¹⁸Myocardial Infarction, E. Johnson, A. A. Aljabali, R. A. Dragovic, M. Rohling, 619 T. G. Belgard, I. A. Udalova, D. R. Greaves, K. M. Channon, P. R. Riley, D. C. 620 Anthony, R. P. Choudhury, Endothelium-derived extracellular vesicles ⁶²¹promote splenic monocyte mobilization in myocardial infarction. *JCI Insight* **²**, ⁶²²7;2(17):e93344 (2017).
- ⁶²³25. C. Thery, K. W. Witwer, E. Aikawa, M. J. Alcaraz, J. D. Anderson, R. 624 Andriantsitohaina, A. Antoniou, T. Arab, F. Archer, G. K. Atkin-Smith, D. C. ⁶²⁵Ayre, J. M. Bach, D. Bachurski, H. Baharvand, L. Balaj, S. Baldacchino, N. N. 626 Bauer, A. A. Baxter, M. Bebawy, C. Beckham, A. Bedina Zavec, A. 627 Benmoussa, A. C. Berardi, P. Bergese, E. Bielska, C. Blenkiron, S. Bobis-⁶²⁸Wozowicz, E. Boilard, W. Boireau, A. Bongiovanni, F. E. Borras, S. Bosch, C. ⁶²⁹M. Boulanger, X. Breakefield, A. M. Breglio, M. A. Brennan, D. R. Brigstock, 630 A. Brisson, M. L. Broekman, J. F. Bromberg, P. Bryl-Gorecka, S. Buch, A. H. 631 Buck, D. Burger, S. Busatto, D. Buschmann, B. Bussolati, E. I. Buzas, J. B. 632 Byrd, G. Camussi, D. R. Carter, S. Caruso, L. W. Chamley, Y. T. Chang, C. ⁶³³Chen, S. Chen, L. Cheng, A. R. Chin, A. Clayton, S. P. Clerici, A. Cocks, E. 634 Cocucci, R. J. Coffey, A. Cordeiro-da-Silva, Y. Couch, F. A. Coumans, B. ⁶³⁵Coyle, R. Crescitelli, M. F. Criado, C. D'Souza-Schorey, S. Das, A. Datta

- 29. X. Loyer, I. Zlatanova, C. Devue, M. Yin, K. Y. Howangyin, P. Klaihmon, C. L. Guerin, M. Kheloufi, J. Vilar, K. Zannis, B. K. Fleischmann, D. W. Hwang, J. 716 Park, H. Lee, P. Menasche, J. S. Silvestre, C. M. Boulanger, Intra-Cardiac 717 Release of Extracellular Vesicles Shapes Inflammation Following Myocardial **Infarction.** *Circulation research* **123**, 100-106 (2018).
- 30. M. Cheng, J. Yang, X. Zhao, E. Zhang, Q. Zeng, Y. Yu, L. Yang, B. Wu, G. Yi, 720 X. Mao, K. Huang, N. Dong, M. Xie, N. A. Limdi, S. D. Prabhu, J. Zhang, G. 721 Qin, Circulating myocardial microRNAs from infarcted hearts are carried in exosomes and mobilise bone marrow progenitor cells. *Nature communications* **¹⁰**, 959 (2019).
- 31. E. A. Ross, M. R. Douglas, S. H. Wong, E. J. Ross, S. J. Curnow, G. B. Nash, E. Rainger, D. Scheel-Toellner, J. M. Lord, M. Salmon, C. D. Buckley, **Interaction between integrin alpha9beta1 and vascular cell adhesion** molecule-1 (VCAM-1) inhibits neutrophil apoptosis. *Blood* **¹⁰⁷**, 1178-1183 (2006).
- 32. N. Ruparelia, J. E. Digby, A. Jefferson, D. J. Medway, S. Neubauer, C. A. Lygate, R. P. Choudhury, Myocardial infarction causes inflammation and leukocyte recruitment at remote sites in the myocardium and in the renal glomerulus. *Inflamm Res* **⁶²**, 515-525 (2013).
- 33. A. M. Akhtar, J. E. Schneider, S. J. Chapman, A. Jefferson, J. E. Digby, K. 734 Mankia, Y. Chen, M. A. McAteer, K. J. Wood, R. P. Choudhury, In vivo quantification of VCAM-1 expression in renal ischemia reperfusion injury using

- ⁷³⁶non-invasive magnetic resonance molecular imaging. *PloS one* **⁵**, e12800 ⁷³⁷(2010).
- ⁷³⁸34. L. Osborn, C. Hession, R. Tizard, C. Vassallo, S. Luhowskyj, G. Chirosso, R. ⁷³⁹Lobb, Direct Expression Cloning of Vascular Cell-Adhesion Molecule-1, a ⁷⁴⁰Cytokine-Induced Endothelial Protein That Binds to Lymphocytes. *Cell* **⁵⁹**, 741 1203-1211 (1989).
- ⁷⁴²35. V. Agarwal, G. W. Bell, J. W. Nam, D. P. Bartel, Predicting effective ⁷⁴³microRNA target sites in mammalian mRNAs. *Elife* **⁴**, (2015).
- ⁷⁴⁴36. C. Sticht, C. De La Torre, A. Parveen, N. Gretz, miRWalk: An online resource ⁷⁴⁵for prediction of microRNA binding sites. *PloS one* **¹³**, e0206239 (2018).
- ⁷⁴⁶37. W. Liu, X. Wang, Prediction of functional microRNA targets by integrative ⁷⁴⁷modeling of microRNA binding and target expression data. *Genome Biol* **²⁰**, 748 18 (2019).
- 749 38. B. Jassal, L. Matthews, G. Viteri, C. Gong, P. Lorente, A. Fabregat, K. 750 Sidiropoulos, J. Cook, M. Gillespie, R. Haw, F. Loney, B. May, M. Milacic, K. 751 Rothfels, C. Sevilla, V. Shamovsky, S. Shorser, T. Varusai, J. Weiser, G. Wu, ⁷⁵²L. Stein, H. Hermjakob, P. D'Eustachio, The reactome pathway ⁷⁵³knowledgebase. *Nucleic acids research* **⁴⁸**, D498-D503 (2019).
- ⁷⁵⁴39. E. Vafadarnejad, G. Rizzo, L. Krampert, P. Arampatzi, A. P. Arias-Loza, Y. 755 Nazzal, A. Rizakou, T. Knochenhauer, S. R. Bandi, V. A. Nugroho, D. J. J. 756 Schulz, M. Roesch, P. Alayrac, J. Vilar, J. S. Silvestre, A. Zernecke, A. E. 757 Saliba, C. Cochain, Dynamics of Cardiac Neutrophil Diversity in Murine
- ⁷⁵⁸Myocardial Infarction. *Circulation research* **¹²⁷**, e232-e249 (2020).

- 40. S. M. Davidson, J. A. Riquelme, Y. Zheng, J. M. Vicencio, S. Lavandero, D.
- M. Yellon, Endothelial cells release cardioprotective exosomes that may contribute to ischaemic preconditioning. *Scientific reports* **⁸**, 15885 (2018).
- 41. E. Arner, N. Mejhert, A. Kulyte, P. J. Balwierz, M. Pachkov, M. Cormont, S. Lorente-Cebrian, A. Ehrlund, J. Laurencikiene, P. Heden, K. Dahlman-Wright,
- 764 J. F. Tanti, Y. Hayashizaki, M. Ryden, I. Dahlman, E. van Nimwegen, C. O. 765 Daub, P. Arner, Adipose tissue microRNAs as regulators of CCL2 production
- in human obesity. *Diabetes* **⁶¹**, 1986-1993 (2012).
- 42. J. Agudo, A. Ruzo, N. Tung, H. Salmon, M. Leboeuf, D. Hashimoto, C. Becker, L. A. Garrett-Sinha, A. Baccarini, M. Merad, B. D. Brown, The miR-126-VEGFR2 axis controls the innate response to pathogen-associated 770 nucleic acids. *Nat Immunol* **15**, 54-62 (2014).
- 43. V. Rusinkevich, Y. Huang, Z.-y. Chen, W. Qiang, Y.-g. Wang, Y.-f. Shi, H.-t. 772 Yang, Temporal dynamics of immune response following prolonged myocardial ischemia/reperfusion with and without cyclosporine A. *Acta Pharmacologica Sinica* **⁴⁰**, 1168-1183 (2019).
- 775 44. K. J. Eash, J. M. Means, D. W. White, D. C. Link, CXCR4 is a key regulator of 776 and neutrophil release from the bone marrow under basal and stress granulopoiesis conditions. *Blood* **¹¹³**, 4711-4719 (2009).
- 45. B. T. Suratt, J. M. Petty, S. K. Young, K. C. Malcolm, J. G. Lieber, J. A. Nick, 779 J. A. Gonzalo, P. M. Henson, G. S. Worthen, Role of the CXCR4/SDF-1 chemokine axis in circulating neutrophil homeostasis. *Blood* **¹⁰⁴**, 565-571 (2004).
- 46. E. Garcia-Ramallo, T. Marques, N. Prats, J. Beleta, S. L. Kunkel, N. Godessart, Resident cell chemokine expression serves as the major

mechanism for leukocyte recruitment during local inflammation. *J Immunol* **169**, 6467-6473 (2002).

808 activation antigen-4 integrins suppresses neutrophil and T-lymphocyte

⁸⁰⁹migration to the joints and improves clinical disease. *Immunology* **⁸⁸**, 569-576 810 (1996).

- 811 53. C. Bellanné-Chantelot, B. Schmaltz-Panneau, C. Marty, O. Fenneteau, I. 812 Callebaut, S. Clauin, A. Docet, G.-L. Damaj, T. Leblanc, I. Pellier, C. Stoven, 813 S. Souquere, I. Antony-Debré, B. Beaupain, N. Aladjidi, V. Barlogis, F. 814 Bauduer, P. Bensaid, O. Boespflug-Tanguy, C. Berger, Y. Bertrand, L. 815 Carausu, C. Fieschi, C. Galambrun, A. Schmidt, H. Journel, F. Mazingue, B. 816 Nelken, T. C. Quah, E. Oksenhendler, M. Ouachée, M. Pasquet, V. Saada, F. 817 Suarez, G. Pierron, W. Vainchenker, I. Plo, J. Donadieu, Mutations in the 818 SRP54 gene cause severe congenital neutropenia as well as Shwachman-819 **Diamond-like syndrome.** *Blood* **132**, 1318-1331 (2018).
- ⁸²⁰54. Y. Mizoguchi, S. Hesse, M. Linder, N. Zietara, M. Lyszkiewicz, Y. Liu, M. 821 Tatematsu, P. Grabowski, K. Ahomaa, T. Jeske, S. Hollizeck, E. Rusha, M. K. 822 Saito, M. Kobayashi, Z. Alizadeh, Z. Pourpak, S. Iurian, N. Rezaei, E. Unal, 823 M. Drukker, B. Walzog, F. Hauck, J. Rappsilber, C. Klein, Defects in Signal 824 Recognition Particle (SRP) Components Reveal an Essential and Non-825 Redundant Role for Granule Biogenesis and Differentiation of Neutrophil ⁸²⁶Granulocytes. *Blood* **¹³⁴**, 216-216 (2019).
- ⁸²⁷55. A. Hoshino, B. Costa-Silva, T. L. Shen, G. Rodrigues, A. Hashimoto, M. Tesic 828 Mark, H. Molina, S. Kohsaka, A. Di Giannatale, S. Ceder, S. Singh, C. 829 Williams, N. Soplop, K. Uryu, L. Pharmer, T. King, L. Bojmar, A. E. Davies, Y. 830 Ararso, T. Zhang, H. Zhang, J. Hernandez, J. M. Weiss, V. D. Dumont-Cole, 831 K. Kramer, L. H. Wexler, A. Narendran, G. K. Schwartz, J. H. Healey, P. 832 Sandstrom, K. J. Labori, E. H. Kure, P. M. Grandgenett, M. A. Hollingsworth, 833 M. de Sousa, S. Kaur, M. Jain, K. Mallya, S. K. Batra, W. R. Jarnagin, M. S.

Acknowledgments

Statement of Contribution

852 NA isolated, characterized, and utilized EVs in the described experiments and 853 performed western blots, RT-qPCR, chemokine arrays, analysis of infarcted hearts 854 and assisted with *in silico* bioinformatics. ATB, CL, EL, LE, GM, EM, CvS assisted 855 with experimentation. EEC, GJK and CvS undertook antagomiR experiments. ATB 856 performed bioinformatics analysis and generated transcriptome analysis graphs and 857 heat maps. ALC and DP prepared and analysed flow cytometry preparations. AC,

858 RD and EJ imaged EVs by TEM /Cryo-TEM. MGH performed some AMI surgeries. 859 TK and CB performed RNA sequencing. JR performed CRISPR-cas9 base editing of 860 endothelial cells. KJM, PR, KM and DCA led animal investigations. RC and KMC led 861 human AMI investigations. NA and RC conceived the study. All authors participated 862 in study design, coordination and helped to draft the manuscript. All authors have 863 seen the final version of the manuscript and approve of its submission.

864

865 The authors thank the staff at the Oxford Heart Centre for the clinical care of patients 866 recruited in the coordination of the OxAMI study. Phil Townsend and Steve 867 Woodhouse are gratefully acknowledged for general laboratory management. The 868 authors thank biomedical services staff for their expert care of mice used in this 869 study. The OxAMI study is supported by the British Heart Foundation (BHF; grant 870 CH/16/1/32013 to KMC), the BHF Centre of Research Excellence, Oxford 871 (RG/13/1/30181), the National Institute for Health Research Biomedical Research 872 Centre, Oxford and the and the Biomedical Sequencing Facility (BSF) at CeMM for 873 assistance with next-generation sequencing. See Supplemental Acknowledgments 874 for OxAMI details.

875

⁸⁷⁶**Funding**

877 NA and RC acknowledge support by research grants from the British Heart 878 Foundation (BHF) Centre of Research Excellence, Oxford (NA and RC: 879 RE/13/1/30181), British Heart Foundation Project Grant (NA and RC: 880 PG/18/53/33895), the Tripartite Immunometabolism Consortium, Novo Nordisk 881 Foundation (RC: NNF15CC0018486), Oxford Biomedical Research Centre (BRC),

882 Nuffield Benefaction for Medicine and the Wellcome Institutional Strategic Support 883 Fund (ISSF) (NA), the National Institutes of Health (NIHR) ⁸⁸⁴(R35HL135799,P01HL131478 (KJM) and T32HL098129 (CvS)) and the American 885 Heart Association (19CDA346300066 (CvS)). DRFC and GM acknowledge BBSRC 886 (BB/P006205/1). The views expressed are those of the author(s) and not necessarily 887 those of the NHS, the NIHR or the Department of Health

⁸⁸⁹**Figures and Figure Legends**

⁸⁹⁰**Figure 1. Human peripheral blood neutrophils correlate with the extent of** ⁸⁹¹**myocardial injury in AMI**. **A** Pearson's correlation of peripheral blood neutrophil 892 number (10 $⁹$ / L) in patients experiencing AMI significantly correlated with the extent</sup> 893 of myocardial injury (T2-weight MRI) and **B** LGE MRI 6-months post-AMI ($n = 15$). **C** ⁸⁹⁴Schematic representation of mouse AMI and tissue harvesting for flow cytometry. **^D** 895 Percentage of neutrophils in peripheral blood, spleen, bone marrow and heart 2 896 hours after AMI relative to the levels of intact controls (controls $n = 4$, AMI $n = 3$). **E** 897 Mean fluorescence intensity (MFI) of CD62L/L-selectin on neutrophils in peripheral 898 blood, spleen, bone marrow and heart 2 hours after AMI relative to the levels of 899 intact controls (controls $n = 4$, AMI $n = 3$). **F** Percentage of monocytes in peripheral ⁹⁰⁰blood, spleen, bone marrow and heart 2 hours after AMI relative to the levels of 901 intact controls (controls $n = 4$, AMI $n = 3$). Pearson's correlation was used in **A** and ⁹⁰²**B**, dotted lines represent 95% confidence interval and an unpaired t test was used 903 in **D**, **E** and **F** for statistical analysis. Error bars represent mean \Box + \Box SD ** $p\Box$ < \Box 0.01, 904 ^{***}*p*□<□0.001.

905

⁹⁰⁷**Figure 2. Plasma extracellular vesicles (EVs) are elevated in peripheral blood** 908 **following AMI. A** Plasma EV number (10⁸ / mL) at time of presentation following 909 AMI and 6 months later in the same patients $(n = 15)$. **B** Size and concentration 910 profile of plasma EVs at time of presentation following AMI and 6 months later in the 911 same patients ($n = 15$). Pearson's correlation of plasma EVs at time of presentation 912 versus: **C** extent of myocardial injury as determined by T2-weighted MRI, **D** LGE 6-913 months post-AMI, E number of peripheral blood neutrophils following AMI (10⁹ / L) (*n* ⁹¹⁴= 15). A paired t test was used for statistical analysis in **A** and **B**. Pearson's 915 correlation was used in **C**, **D** and **E**, dotted lines represent 95% confidence interval 916 for statistical analysis. ***p* \square <0.01

⁹¹⁸**Figure 3. Human umbilical cord vein endothelial cells (HUVEC) release more** ⁹¹⁹**extracellular vesicles (EVs) after inflammatory stimulation**. **A** HUVECs: express 920 more VCAM-1 following treatment with recombinant human tumour necrosis factor-α 921 (TNF-α) (10 ng / mL) $(n = 9$ per group); **B** release more EVs $(n = 8$ per group). **C** 922 Size and concentration profile of HUVEC derived EVs under basal conditions and 923 after inflammatory stimulation with recombinant human TNF- α (*n* = 8 per group). **D** 924 Transmission electron micrograph (TEM) of HUVEC-derived EVs (scale bar 100 nm) ⁹²⁵and **E** cryo-TEM HUVEC-derived EVs (scale bar 50 nm). **F** Ponceau stain and 926 western blot of HUVEC derived EV from basal and after inflammatory stimulation 927 with TNF-α for eNOS, TSG101, CD9, ATP5A and Histone H3. HUVEC cell pellets ⁹²⁸(CP), EV-depleted cell culture supernatants (EV-dep) and cell culture media that was 929 not exposed to cells (sham) were used as controls. EC-EV miRNA levels of **G** hsa-⁹³⁰miRNA-126-3p and **H** hsa-miRNA-126-5p under basal conditions and after 931 inflammatory stimulation with TNF- α ($n = 8$ per group). miRNA-126-mRNA targets in ⁹³²human and mouse and their target pathways. **I** Euler plot of miRNA-126-mRNA 933 targets from TargetScanHuman, TargetScanMouse, miRWalk, miRDB for human 934 and the mouse. **J** Euler plot of Gene Ontology (GO) terms for miRNA-126-mRNA 935 targets for the human and mouse. Shape areas are approximately proportional to 936 number of genes. An unpaired t test was used in **A**, **B**, **C**, **G** and **H** for statistical 937 analysis. Error bars represent mean $\exists \pm SD$ ** $p\Box < \Box 0.01$, *** $p\Box < \Box 0.001$.

⁹³⁹**Figure 4. RNA sequencing of peripheral blood neutrophils** following STEMI and 940 NSTEMI patients at the time of presentation versus a control sample obtained from 941 the same patients 1 month post-AMI ($n = 3$ per group). MA plots shows differential 942 transcriptome at the time of presentation versus a control sample obtained from the ⁹⁴³same patients 1 month post-AMI in **A** NSTEMI and **B** STEMI patients. Significantly 944 altered genes are highlighted in red. **C** Euler plot showing similarity and differences 945 in the number of differentially expressed genes in NSTEMI and STEMI patients at 946 time of presentation versus 1 month follow-control samples or between all NSTEMI 947 and all STEMI patients ($n = 3$ per group). **D** Normalised enrichment scores are 948 shown for significantly enriched Hallmark gene sets from gene set enrichment 949 analysis (GSEA) of presentation versus 1 month follow-control samples from STEMI 950 patients $(n = 3)$. **E** miRNA-126 antagomiR treatment of wild-type mice prior to 951 induction of AMI. **F** TTC staining of the myocardium 24 hours post-AMI in scramble 952 and antagomiR treated mice (scramble $n = 7$ and antagomiR $n = 5$ per group). ⁹⁵³Significant differentially expressed (DE) genes in **A**, **B** and **C** were determined by 954 adjusted *p*-values below the 5% false discovery rate (FDR) threshold. Significantly 955 enriched gene sets in **D** were defined as having a Benjamini–Hochberg-adjusted 956 *p*<0.05. **F** an unpaired t test was used for analysis. Error bars represent mean□± SD 957 ^{**}*p*□<□0.01.

⁹⁵⁹**Figure 5 Mouse sEND.1 endothelial cells release more extracellular vesicles** ⁹⁶⁰**(EVs) after inflammatory stimulation. ^A** mouse sEND.1 endothelial cells express 961 more VCAM-1 following treatment with recombinant mouse tumour necrosis factor-α ⁹⁶²(TNF-α) (10 ng / mL) (*n* = 9 per group); **B** release more EVs (*n* = 11 per group). **^C** 963 Size and concentration profile of sEND.1 derived EVs under basal conditions ($n = 3$) 964 and after inflammatory stimulation with recombinant mouse TNF- α ($n = 4$). **D** 965 Transmission electron micrograph (TEM) of sEND.1-derived EVs (scale bar 1000 ⁹⁶⁶nm) and **E** cryo-TEM sEND.1-derived EVs (scale bar 1000 nm). **F** Ponceau stain and 967 western blot of sEND.1 derived EV from basal and after inflammatory stimulation 968 with TNF-α for ALIX, TSG101, CD9, eNOS, VCAM-1, ATP5A and Histone H3. 969 sEND1 cell pellets (CP), EV-depleted cell culture supernatants (EV-dep) and cell 970 culture media that was not exposed to cells (sham) were used as controls. EC-EV 971 miRNA levels of **G** hsa-miRNA-126-3p and **H** hsa-miRNA-126-5p under basal 972 conditions ($n = 8$) and after inflammatory stimulation with TNF-α ($n = 7$). An unpaired ⁹⁷³t test was used in **A**, **B**, **C**, **G** and **H** for statistical analysis. Error bars represent 974 mean \Box \pm \Box SD ** p \Box < \Box 0.01, *** p \Box < \Box 0.001.

975

⁹⁷⁷**Figure 6. Endothelial cell derived extracellular vesicles (EC-EV) localise to the** 978 **spleen in wild-type, mice and influence gene and protein expression**. **A** RT-979 qPCR detection of EC-EV labelled with miRNA-39-3p in the spleen of mice following 980 intravenous injection of 1 x 10 9 EVs by tail vein at 2 ($n = 4$), 6 ($n = 4$) and 24 ($n = 6$) 981 hours post-injection. Sham $(n = 10)$ represents a media only preparation control with 982 no EC-EVs. **B** Heat map showing gene expression in the spleen of mice following 983 intravenous injection of 1 x 10 9 EVs by tail vein at 2 ($n = 4$), 6 ($n = 4$) and 24 ($n = 6$) 984 hours post injection. Sham $(n = 10)$ represents a media only preparation control with 985 no EC-EVs. Data shown as $ΔΔCt$ values normalised to row mean $ΔΔCt$ value for 986 each gene. **C** Heat map showing protein expression in the spleen of mice following 987 intravenous injection of 1 x 10⁹ EVs by tail vein at 2 hours ($n = 4$) post-injection. 988 Sham $(n = 4)$ represents a media only preparation control with no EC-EVs. Data 989 shown are chemokine array dot blot density values normalised to mean row value for 990 each protein. A one-way ANOVA with post-hoc Bonferroni correction was used in A, **B** and an unpaired t test was used in **C**. Error bars represent mean \pm SD ⁹⁹²***p*<0.05, ***p*<0.01, ****p*<0.001.

¹⁰⁰⁸**Figure 8. Extracellular vesicle (EV) vascular cell adhesion molecule-1 (VCAM-1)** ¹⁰⁰⁹**is necessary for endothelial cell (EC)-EV splenic-neutrophil mobilisation. ^A** 1010 Transmission electron micrograph of a VCAM-1+ plasma EV bound to a magnetic 1011 bead of iron oxide (MPIO) conjugated with anti-human VCAM-1 antibodies, scale bar 1012 is 200nm. **B/C** Western blot of sEND.1 wild-type and CRISPR-cas9 base-edited 1013 VCAM-1 knock outs cell pellets under basal conditions (wild-type $n = 4$ and VCAM-1 1014 knock out $n = 4$ per group) and after inflammatory stimulation with recombinant ¹⁰¹⁵mouse tumour necrosis (TNF-α). **D** The number of mouse sEND.1 endothelial cell 1016 derived extracellular vesicles (EC-EVs) from wild-type and CRISPR-cas9 base-¹⁰¹⁷edited VCAM-1 knock outs under basal conditions (wild-type *n* = 12 and VCAM-1 1018 knock out $n = 11$ per group) and after inflammatory stimulation with recombinant ¹⁰¹⁹mouse tumour necrosis factor-α (TNF-α) (*n* = 8 per group). **E** Size and concentration 1020 profile of mouse sEND.1 EC-EVs from wild-type and CRISPR/Cas9 base-edited 1021 VCAM-1 knock outs under basal conditions (wild-type $n = 12$ and VCAM-1 knock out ¹⁰²²*n* = 11 per group) and after inflammatory stimulation with recombinant mouse tumour 1023 necrosis factor-α (TNF-α) ($n = 8$ per group). **F** Ponceau stain and western blot of 1024 wild-type and CRISPR-case9 base-edited VCAM-1 knock out sEND.1 derived EVs 1025 from basal and after inflammatory stimulation with recombinant mouse TNF- $α$ for 1026 TSG101, CD9 and VCAM-1. Inflammatory stimulated s.END1 cell pellets and EV-¹⁰²⁷depleted cell culture supernatants were used as controls. **G** RT-qPCR detection of 1028 wild-type sEND.1 and CRISPR-cas9 base-edited VCAM-1 knock outs EC-EV 1029 labelled with miRNA-39-3p in the spleen of mice following intravenous injection of 1 x 1030 10⁹ EVs by tail vein at 2 hours post-injection ($n = 5$ per group). **H** Heat map showing 1031 mRNA expression in the spleen of mice following intravenous injection of wild-type or 1032 CRISPR-cas9 base-edited VCAM-1 knock out EC-EVs 1 x 10^9 EVs by tail vein at 2

1033 hours post-injection. Sham represents a media only preparation control with no EC-¹⁰³⁴EVs (*n* = 5 per group). Data shown as ΔΔCt values normalised to row mean ΔΔCt ¹⁰³⁵value for each gene. **I/J** Percentage of neutrophils as a proportion of the total 1036 leukocytes (live, CD45⁺, CD11b⁺, Ly6G⁺) in peripheral blood and spleen (sham and 1037 VCAM-1 knock out EC-EV *n* = 4 and wild-type EC-EV *n* = 5 per group)**. I** Splenic-1038 neutrophil mobilisation ratio (peripheral blood neutrophils/ spleen neutrophils) shows 1039 net contributions of splenic reserves to mobilised peripheral blood neutrophils 1040 following intravenous injections of wild-type or CRISPR-cas9 base-edited VCAM-1 1041 knock out EC-EVs 1 x 10^9 EVs by tail vein at 2 hours post injection. Sham represents 1042 a media only preparation control with no EC-EVs (sham and VCAM-1 knock out EC-1043 EV $n = 3$ and wild-type EC-EV $n = 5$ per group). One-way (H, I and J) and two-way ¹⁰⁴⁴(**B**, **C, D** and **E**) ANOVA with post-hoc Bonferroni correction was used for statistical 1045 analysis. An unpaired t test was used in **F**. Error bars represent mean□±□SD 1046 $*$ *p* \Box < \Box 0.05, $*$ ^{*}*p* \Box < \Box 0.01, $*$ $*$ $*$ *p* \Box < \Box 0.0001. $*$ $*$ $*$ $*$ p \Box < \Box 0.0001.

¹⁰⁴⁸**Supplementary Table 1** miRNA-126-mRNA targets in the human, mouse and the 1049 overlap between both species.

¹⁰⁵⁰**Supplementary Table 2** miRNA-126-mRNA target pathways using gene ontology 1051 (GO) in the human, mouse and the overlap between both species.

¹⁰⁵²**Supplementary Table 3** P-values are shown from a Fisher's exact test used to 1053 detect enrichment of curated miRNA-126-mRNA targets versus gene sets for 1054 neutrophil GO terms.

¹⁰⁵⁵**Supplementary Table 4** GO biological process and Reactome pathway analysis of 1056 differentially enriched genes in human neutrophils from STEMI patients at the time of 1057 injury.

¹⁰⁵⁸**Supplementary Table 5** GO (biological process, molecular function and cellular 1059 component) and Reactome pathway analysis in single cell RNA-sequencing of 1060 differentially enriched genes in neutrophil blood population 1 follow AMI.

¹⁰⁶¹**Supplementary Table 6** GO (biological process, molecular function and cellular 1062 component) and Reactome pathway analysis in single cell RNA-sequencing of 1063 differentially enriched genes in neutrophil blood population 2 follow AMI.

¹⁰⁶⁴**Supplementary Table 7** GO (biological process, molecular function and cellular 1065 component) and Reactome pathway analysis in single cell RNA-sequencing of 1066 differentially enriched genes in neutrophil blood population 3 follow AMI.

¹⁰⁶⁷**Supplementary Table 8** P-values are shown from a Fisher's exact test used to 1068 detect enrichment of differentially enriched genes in human peripheral blood 1069 neutrophil versus single cell RNA-sequencing of blood neutrophils from the mouse 1070 following AMI.

1071

¹⁰⁷²**Supplementary Table 9** P-values and Jaccard index are shown from a Fisher's ¹⁰⁷³exact test used to detect enrichment of differentially enriched gene target pathways 1074 using GO (biological process, molecular function and cellular component) and ¹⁰⁷⁵Reactome pathway analysis from human peripheral blood neutrophil versus single 1076 cell RNA-sequencing of blood neutrophils from the mouse following AMI.

¹⁰⁷⁷**Supplementary Table 10** miRNA-126-mRNA targets from the human, mouse and 1078 the overlap (present in human and mouse) were compared with differentially 1079 expressed (DE) genes and the not-DE (NDE) genes in the neutrophil transcriptomes 1080 at time of presentation with AMI.

1081 miRNA-126-mRNA targets from the human, mouse and the overlap (present in 1082 human and mouse) were compared with differentially expressed (DE) genes and the 1083 not-DE (NDE) genes in single cell RNA-sequencing of differentially enriched genes 1084 in neutrophil blood and heart populations following AMI.

1085

¹⁰⁸⁶**Supplementary OxAMI.** Author acknowledgments for the Oxford Acute Myocardial 1087 Infarction Study.

1088

¹⁰⁸⁹**Supplementary Methods.** Details of experimental methods and reagents**.**

1090

¹⁰⁹¹**Supplementary uncropped western blots.** Unedited images of western blot 1092 membranes

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

which was not certified by peer review) is the author/funder, who has granted medRxiv a licens)
.All rights reserved. No reuse allowed without permission. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Figure 4

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Figure 7

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

